Safety Shot announced that it has retained attorney Mark Basile and his short and distort securities litigation firm, The Basile Law Firm P.C., to investigate recent activities surrounding the company’s stock performance and to take whatever legal action necessary to prevent potential market participants utilizing unlawful means from further hurting retail investors including the recently published research paper by Capybara Research. Brian S. John, CEO of Safety Shot, Inc., said “We are pleased to welcome Mr. Basile to our legal team. We are committed to legally pursue all short and distort campaigns against the company as well as all media outlets that irresponsibly reported the false, misleading and defaming Capybara Report. Mr. Basile understands how short and distort campaigns negatively affect retail shareholders and will be leading this and other litigation we plan to protect the company and its shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SHOT:
- Safety Shot, Inc Hires Securities Litigation Attorney Mark R. Basile, Esq. and The Basile Law Firm P.C. – Dilution Funding and Short and Distort Experts
- Safety Shot Continues Scientific Development with Double-Blind Placebo-Controlled Trial Designed to Assess the Effects of Safety Shot on Blood and Breath Alcohol Levels
- Safety Shot commences clinical trial of Safety Shot on blood, breath alcohol
- Safety Shot files to sell 1.98M shares of common stock for holders
- Safety Shot says preparing lawsuit against short sellers